Olfactory threshold is impaired in early, active multiple sclerosisLUTTEROTTI, A; VEDOVELLO, M; REINDL, M et al.Multiple sclerosis. 2011, Vol 17, Num 8, pp 964-969, issn 1352-4585, 6 p.Article

Interferon-β_1b augments activation-induced T-cell death in multiple sclerosis patientsKASER, A; DEISENHAMMER, F; BERGER, T et al.Lancet (British edition). 1999, Vol 353, Num 9162, pp 1413-1414, issn 0140-6736Article

Acute cerebellar ataxia after immunisation with recombinant hepatitis B vaccineDEISENHAMMER, F; POHL, P; BÖSCH, S et al.Acta neurologica scandinavica. 1994, Vol 89, Num 6, pp 462-463, issn 0001-6314Article

Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases : a comparative studyREINDL, M; LININGTON, C; BREHM, U et al.Brain. 1999, Vol 122, pp 2047-2056, issn 0006-8950, 11Article

Double-tracer SPECT in patients with AIDS encephalopathy : a comparison of ¹²³I-IMP with ⁹⁹Tc^m-HMPAOPOHL, P; RICCABONA, G; HILTY, E et al.Nuclear medicine communications. 1992, Vol 13, Num 8, pp 586-592, issn 0143-3636Conference Paper

Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicitySOMINANDA, A; ROT, U; SUONIEMI, M et al.Multiple sclerosis. 2007, Vol 13, Num 2, pp 208-214, issn 1352-4585, 7 p.Article

A novel and rapid assay for the detection of neutralizing antibodies against interferon-betaKOH, M; HARVEY, J; SCHAUTZER, F et al.Multiple sclerosis. 2003, Vol 9, Num 1, pp 32-35, issn 1352-4585, 4 p.Article

Comparative study of four different assays for the detection of binding antibodies against interferon-βGNEISS, C; BRUGGER, M; MILLONIG, A et al.Multiple sclerosis. 2008, Vol 14, Num 6, pp 830-836, issn 1352-4585, 7 p.Article

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patientsGNEISS, C; TRIPP, P; BERGER, T et al.Multiple sclerosis. 2006, Vol 12, Num 6, pp 731-737, issn 1352-4585, 7 p.Article

Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injuryFRANZ, G; BEER, R; KAMPFL, A et al.Neurology. 2003, Vol 60, Num 9, pp 1457-1461, issn 0028-3878, 5 p.Article

Anti-MOG and anti-MBP antibody subclasses in multiple sclerosisEGG, R; REINDL, M; DEISENHAMMER, F et al.Multiple sclerosis. 2001, Vol 7, Num 5, pp 285-289, issn 1352-4585Article

Cerebrospinal fluid ferritin in HIV infected patients with acute neurological episodesDEISENHAMMER, F; MILLER, R. F; BRINK, N. S et al.Genitourinary medicine. 1997, Vol 73, Num 3, pp 181-183, issn 0266-4348Article

Methadone-substitution and driving abilityRÖSSLER, H; BATTISTA, H. J; DEISENHAMMER, F et al.Forensic science international. 1993, Vol 62, Num 1-2, pp 63-66, issn 0379-0738Conference Paper

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody developmentHEGEN, H; MILLONIG, A; MALUCCHI, S et al.Multiple sclerosis. 2014, Vol 20, Num 5, pp 577-587, issn 1352-4585, 11 p.Article

High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot studyMILLONIG, A; RUDZKI, D; HÖLZL, M et al.Multiple sclerosis. 2009, Vol 15, Num 8, pp 977-983, issn 1352-4585, 7 p.Article

Smoking is a risk factor for early conversion to clinically definite multiple sclerosisDI PAULI, F; REINDL, M; BERGER, T et al.Multiple sclerosis. 2008, Vol 14, Num 8, pp 1026-1030, issn 1352-4585, 5 p.Article

Vascular endothelial growth factor in CSF : A biological marker for carcinomatous meningitisSTOCKHAMMER, G; POEWE, W; GUNSILIUS, E et al.Neurology. 2000, Vol 54, Num 8, pp 1670-1675, issn 0028-3878Article

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodiesDEISENHAMMER, F; REINDL, M; HARVEY, J et al.Neurology. 1999, Vol 52, Num 6, pp 1239-1243, issn 0028-3878Article

A consensus protocol for the standardization of cerebrospinal fluid collection and biobankingTEUNISSEN, C. E; PETZOLD, A; HINTZEN, R. Q et al.Neurology. 2009, Vol 73, Num 22, pp 1914-1922, issn 0028-3878, 9 p.Article

A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosisCOMABELLA, M; LÜNEMANN, J. D; CABALLERO, E et al.Brain. 2009, Vol 132, pp 3353-3365, issn 0006-8950, 13 p., 12Article

Hemipseudoathetosis due to a hemorrhage at the cervicomedullary junction. Authors' replyGOTKINE, Marc; MOSHE GOMORI, John; GOODIN, Douglas S et al.GOODIN, Douglas S et al.Neurology. 2007, Vol 69, Num 15, pp 1551-1556, issn 0028-3878, 6 p.Article

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativityGNEISS, C; REINDL, M; LUTTEROTTI, A et al.Multiple sclerosis. 2004, Vol 10, Num 5, pp 507-510, issn 1352-4585, 4 p.Article

Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosisEHLING, R; LUTTEROTTI, A; WANSCHITZ, J et al.Multiple sclerosis. 2004, Vol 10, Num 6, pp 601-606, issn 1352-4585, 6 p.Article

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosisFAZEKAS, F; DEISENHAMMER, F; STRASSER-FUCHS, S et al.Lancet (British edition). 1997, Vol 349, Num 9052, pp 589-593, issn 0140-6736Article

Membranöse Lipodystrophie (Morbus Nasu-Hakola) = Membranous lipodystrophy (Nasu-Hakola disease)DEISENHAMMER, F; WILLEIT, J; SCHMIDAUER, C et al.Nervenarzt. 1993, Vol 64, Num 4, pp 263-265, issn 0028-2804Article